Birch triterpenes is a Small Molecule owned by Amryt Pharma, and is involved in 10 clinical trials, of which 9 were completed, and 1 is ongoing.

Oleogel-S-10 comprises of non-polar liquid and a powder containing betulin (a triterpene). Oleogel-S-10 accelerates the epithelialization of skin and wound healing process. Triterpenes may influence the inflammatory phase of wound healing by upregulating pro-inflammatory cytokines, chemokines and cyclooxygenase-2 (COX-2) in human primary keratinocytes. It increase the formation of actin filopodia, lamellipodia and stress fibers, processes that are dependent on the activation of Rho GTPases and it improves epidermal regeneration and accelerates the repair of the epidermal barrier function and helps in wound healing process.

The revenue for Birch triterpenes is expected to reach a total of $689m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Birch triterpenes NPV Report.

Birch triterpenes is currently owned by Amryt Pharma.

Birch triterpenes Overview

Birch bark extract (Oleogel-S10, Filsuvez, Episalvan) from Betula pendula Roth/ Betula pubescens Ehrh is an herbal extract acts as dermatological agent. Oleogel-S10 contains a triterpene extract from birch bark as active ingredient. Triterpenes are terpenes consisting of six isoprene units. It is formulated as gel for topical and cutaneous application. It is indicated for the treatment of partial thickness wounds in adults. The drug cantains 72-88 percent betulin (a triterpene).

The drug candidate is under development for the treatment of stevens johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and radiation induced dermatitis. The drug candidate is administered topically. It was also under development for the treatment of actinic keratoses and epidermolysis bullosa (dystrophic epidermolysis bullosa/junctional epidermolysis bullosa).

Amryt Pharma Overview

Amryt Pharma (Amryt) is a biopharmaceutical company that develops and commercializes novel treatments for patients with rare and orphan diseases. It has two marketed products including lomitapide for the treatment of adult HoFH and Metreleptin for the treatment of leptin deficiency. The company is also developing a portfolio of pipeline candidates, Oleogel-S10 and AP103 targeting multiple orphan diseases such as epidermolysis bullosa. The company offers its products in the US, Europe, the Middle East and Africa (EMEA). Amryt Pharma is headquartered in London, the UK.

The company reported revenues of (US Dollars) US$222.5 million for the fiscal year ended December 2021 (FY2021), an increase of 21.9% over FY2020. The operating loss of the company was US$38.6 million in FY2021, compared to an operating loss of US$46.5 million in FY2020. The net profit of the company was US$1 million in FY2021, compared to a net loss of US$104.5 million in FY2020. The company reported revenues of US$61.1 million for the third quarter ended September 2022, a decrease of 10.8% over the previous quarter.

Quick View – Birch triterpenes

Report Segments
  • Innovator (NME)
Drug Name
  • Birch triterpenes
Administration Pathway
  • Cutaneous
  • Topical
Therapeutic Areas
  • Dermatology
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.